CME Group: the toll bridge that gets paid on both fear and greed
CME Group: the toll bridge that gets paid on both fear and greed
CME Group is not a bank. It is not a broker. It is not a hedge fund. It is the venue — the place where futures and options on interest rates, equities, energy, metals, and agricultural commodities change hands, and the clearing house that guarantees every one of those trades. It earns a fee on every contract, a subscription on every data terminal, and carries none of the directional risk.
In FY2025, CME Group processed an average of roughly 27 million contracts per day. Revenue reached $6.52 billion. Net income was $4.07 billion — a 62.4% net margin. Operating cash flow was $4.28 billion, meaning more than 65 cents of every revenue dollar converts directly to cash.
This is one of the widest-moat businesses in financial services. The question is not whether the moat exists, but how to separate the durable economics from the cyclical surface noise, and what mental model carries over to adjacent industries.
What CME Group actually does
The company owns four exchanges: CME (Chicago Mercantile Exchange), CBOT (Chicago Board of Trade), NYMEX (New York Mercantile Exchange), and COMEX (Commodity Exchange). It also owns CME Clearing, the clearing house that sits between every buyer and seller, and BrokerTec (cash US Treasuries) and EBS (spot FX) acquired with NEX Group in 2018.
The product mix, roughly, from the 2025 10-K:
- Interest rates (Eurodollar, SOFR, Treasury futures and options): the dominant franchise. Interest rate products are the volume and revenue anchor — think 40-45% of clearing and transaction fees. CME's Treasury complex is the global benchmark for US rate risk transfer.
- Equity indices (S&P 500, Nasdaq-100, E-mini, Micro): a second pillar, perhaps 20-25% of fees. The S&P 500 futures contract is the most liquid equity derivative in the world.
- Energy (WTI crude oil, Henry Hub natural gas, refined products): the NYMEX franchise, maybe 15-18% of fees.
- Agricultural commodities (corn, soybeans, wheat, livestock): the original CBOT/CME franchise, smaller now in proportion, perhaps 5-8%.
- Metals (gold, silver, copper on COMEX): another smaller but deeply entrenched franchise.
- Foreign exchange (FX futures and options, plus EBS spot FX): modest share of total fees.
Revenue breaks into three streams:
| Source | Approximate share | Economics |
|---|---|---|
| Clearing and transaction fees | ~84% | Per-contract fee × volume. High incremental margin — each additional contract costs near zero to process. |
| Market data and information services | ~10% | Recurring subscription revenue from terminals, data feeds, and analytics. High retention. |
| Other (access, communication, custody) | ~6% | Co-location fees, connectivity charges, portfolio margining services. |
The fundamental dynamic: revenue follows trading volume, which follows volatility and structural market growth. In calm years, volume slows. In crisis years, volume surges. CME is a toll bridge that gets paid on traffic — and traffic is highest when markets are most uncertain.
Industry mechanics: how the exchange business works
The product: standardized risk transfer
A futures contract is a legally binding agreement to buy or sell something at a specified price on a specified future date. The exchange standardizes the contract terms — quantity, quality grade, delivery location, expiration cycle. Standardization makes the contract fungible, which enables a liquid secondary market.
A futures exchange is not a prediction market, though it produces prices that look like predictions. It is a risk transfer mechanism. Commercial hedgers — farmers, oil producers, bond portfolio managers — use futures to lock in prices and offload risk. Speculators provide the other side of the trade, absorbing the risk in exchange for potential profit. Both sides need each other, and both need a venue where they can execute with confidence.
How money flows through the chain
- A trade is executed on CME Globex (the electronic platform) or via a broker who routes it there.
- CME Clearing becomes the central counterparty — the buyer to every seller and the seller to every buyer — eliminating bilateral credit risk.
- Both sides post margin (performance bonds) with the clearing house. Initial margin plus daily variation margin ensures that if one side defaults, the other side is protected.
- CME earns a fee per contract from both the clearing fee and the exchange fee. The combined fee is typically $0.50-1.50 per contract depending on product, volume tier, and customer type.
Where the profit is captured
The exchange captures profit at the transaction layer — not from market-making, not from directional bets, not from balance sheet spread. Each trade generates a fee. The incremental cost of processing one more contract is essentially zero: Globex servers, clearing algorithms, and data center bandwidth are fixed costs.
This produces what might be the highest-quality operating leverage in financial services.
Who bears balance-sheet risk
Critically, CME does not bear the counterparty risk — the clearing house structure shifts it to the clearing members (large banks and brokers) who guarantee their clients' obligations, and to the margin collateral itself. CME Clearing's own capital is a backstop, but in practice, the default waterfall is: defaulting member's margin → defaulting member's contribution to the guarantee fund → CME's own contribution → assessments on surviving members. CME's capital is the third-highest layer in the stack.
The enormous balance sheet seen in SEC filings ($198 billion in assets at end of FY2025) is not CME's operating capital — it is client margin cash held in segregation. The operating company's cash was approximately $4.4 billion. This distinction is essential: CME's balance sheet looks like a giant bank because it holds customer collateral, but the actual shareholder equity is $28.7 billion, and the income-generating assets are mostly the technology stack, the regulatory licenses, and the liquidity network.
Hidden constraints
- Regulation: CME operates as a Designated Contract Market (DCM) and Derivatives Clearing Organization (DCO) under CFTC oversight. It is also a Self-Regulatory Organization (SRO), meaning it writes and enforces its own rulebook (subject to CFTC approval). This license is not easy to get and harder to keep.
- Liquidity gravity: The single most important constraint on any competitor is getting enough volume to make the market tight enough to attract the next trader. Once a contract achieves critical mass, competing contracts for the same underlying almost always fail.
- Technology availability: Co-location, deterministic latency, and Globex API access are not just features — they are the table stakes of modern derivatives trading. CME has spent billions building and maintaining them.
- Clearing membership: FCMs (Futures Commission Merchants) must be members to clear client trades. The clearing member network is itself a barrier.
Moat analysis: 7 Powers applied to CME Group
1. Network Economies — the anchor power
This is the dominant moat, and it operates at two levels.
Trader-level network effects. A trader wants to execute where the order book is deepest, the bid-ask spread is tightest, and the market impact of their own order is smallest. All three are functions of the number of other traders present. More traders → deeper book → tighter spread → more attractive venue → more traders. This is the classic liquidity flywheel.
Product-level network effects. A Treasury futures contract hedges exposure to US government bonds. The more end-users who use CME's Treasury contracts to manage their portfolio risk, the more relevant the contract becomes for every other end-user. An asset manager benchmarks their hedge ratio against market convention. If CME's Treasury complex is the convention, using ICE's competing Treasury contracts creates tracking error against peers. This norming effect — "everyone hedges here, so I must hedge here" — extends the moat beyond pure execution quality into institutional behavior.
Evidence of the force. There is a long graveyard of futures contracts that failed to compete with incumbent listings. ICE has tried multiple times to launch Treasury futures — none have achieved meaningful volume. Eurex tried to take share in Eurodollar futures when CME was transitioning to SOFR during LIBOR cessation — early volume spiked, then collapsed once the transition stabilized. Cboe's attempt at competing equity index futures has been marginal.
The pattern is consistent: a competitor can launch a functionally identical contract at a lower fee, but unless they can also deliver the liquidity — the tight market, the depth of book, the implicit guarantee of immediate execution — most volume stays put.
When network effects fail. The key exception to note: Eurex successfully built a competing Euro STOXX 50 futures market in Europe because LIFFE was slow to go electronic and lost its liquidity advantage. The lesson is that network effects are durable but not indestructible — a technology transition, a regulatory change, or a prolonged period of competitor subsidization can flip liquidity when the incumbent stumbles. CME has not stumbled.
2. Scale Economies
CME's fixed-cost technology infrastructure — Globex data centers in Aurora, Illinois; the clearing engine; the regulatory compliance apparatus; the market surveillance systems — serves billions of contracts annually. The average fixed cost per contract is negligible.
This creates a second-order effect: CME can invest more in technology, security, and resilience than any smaller competitor because it can amortize those costs over far more volume. The rich-get-richer dynamic is strongest in the exchange business.
A new entrant cannot be a "lean startup" in this industry. The regulatory capital requirements, technology infrastructure, and compliance staffing are non-negotiable fixed costs. Building to parity from zero would cost billions and take years. And at the end, the entrant still wouldn't have the liquidity.
3. Counter-Positioning
In the 1990s and early 2000s, incumbent exchanges — particularly in Europe — were slow to move from open-outcry pits to electronic trading. LIFFE (London) maintained floor trading while Eurex built a fully electronic platform and captured the Bund futures volume that became Europe's benchmark. LIFFE never recovered.
CME and CBOT were early and aggressive in the electronic transition. CME launched Globex in 1992 and relentlessly pushed volume onto the platform. Today, effectively 100% of volume is electronic. No floor-based exchange can counter-position against CME — the electronic transition is complete, and the incumbent is the electronic leader. The next threat would come from a structurally different venue type, such as a decentralized protocol, but that is a different kind of challenge — see the risk section.
4. Switching Costs
A large bank or trading firm's connection to CME is not a simple account. It involves:
- FCM clearing membership with legal agreements, capital commitments, and operational integration
- Co-location hardware installed in CME's data center, with deterministic fiber paths
- Software systems (execution algorithms, risk engines, back-office settlement) built around CME's APIs and message formats
- Staff trained on CME-specific workflows
- Market data infrastructure calibrated to CME's feed formats
Moving a material share of volume to a competitor means duplicating or rebuilding most of this. And you would only make that investment if the competitor's market offered better execution — which it almost certainly doesn't, because it lacks the liquidity. This is a classic "chicken and egg" switching cost trap.
5. Branding
"CME" and "CBOT" are not consumer brands, but they are institutional trust signals. A corporate treasurer hedging interest rate exposure, a pension fund managing duration, or an airline locking in jet fuel prices chooses CME because it is the benchmark. The brand communicates: this contract will settle, the clearing house will perform, and the regulator has approved it.
This matters in a way that is easy to underestimate. After the 2008 financial crisis, CME Clearing was one of the few parts of the financial plumbing that did not fail, require a bailout, or trigger collateral calls that broke counterparties. That operational history is a reputational asset that a new entrant cannot buy.
6. Cornered Resource
The "resource" here is the regulatory license. CME holds DCM and DCO designations from the CFTC — the right to operate a US futures exchange and a US derivatives clearing house. These are not theoretically impossible to obtain, but the process is measured in years, requires demonstrated capitalization and operational capability, and faces political scrutiny.
CME's SRO status adds a second, subtler resource: the ability to write its own market rules and enforce them, subject to CFTC oversight. This means CME can adapt its rulebook faster than a competitor that relies on a separate SRO — and can design rules that inadvertently (or deliberately) make it harder for competing contracts to gain footholds.
Additionally, the exclusive licensing agreement with S&P Dow Jones Indices for S&P 500 and Dow Jones futures is a cornered intellectual property asset. No competitor can legally list an S&P 500 futures contract.
7. Process Power
CME Clearing's risk management procedures — intraday margining, stress testing, default management drills, guarantee fund sizing, cross-margining algorithms — are not documented in a training manual. They are embedded in decades of institutional experience, regulatory reviews, and crisis responses.
The clearing house managed 2008 without a default. It managed March 2020 (when volatility hit levels not seen since 1987) without a single clearing member failure. It managed the 2022 UK gilt crisis and the 2023 banking turmoil. Process power in clearing is not a competitive advantage in the marketing sense — it is a minimum requirement, and the gap between CME's demonstrated capability and a new entrant's theoretical capability is a real barrier.
Moat summary
| Power | Strength | Mechanism |
|---|---|---|
| Network Economies | Dominant | Liquidity → tighter spreads → more volume → more liquidity. Compound effect. |
| Scale Economies | Strong | Fixed cost amortization over billions of contracts. Tech investment gap widens over time. |
| Counter-Positioning | Weak (historical) | Electronic transition was the counter-positioning moment. That era is over. |
| Switching Costs | Strong | Co-lo, APIs, member agreements, staff training. High fixed cost to move. |
| Branding | Strong | Institutional trust and regulatory track record. S&P 500 contract is a household name among institutions. |
| Cornered Resource | Strong | CFTC licenses, SRO status, S&P index exclusivity. |
| Process Power | Strong | Clearing house operational reliability proven through multiple crises. |
The moat is real, multi-layered, and mutually reinforcing. The network effect is the engine. The regulatory barrier, switching costs, and process power are moats around the moat — they make the core advantage harder to challenge.
Porter's Five Forces
Rivalry among competitors — moderate to high, but fragmented by product
CME, Intercontinental Exchange (ICE), and Cboe Global Markets are the three US exchange groups. Globally, Eurex is the European competitor, and various national exchanges exist in Asia.
The rivalry is real at the corporate level — all three compete for listings, for technology talent, and for attention from regulators and legislators. But at the product level, competition is muted by the liquidity incumbency: CME dominates US rates and equities, ICE dominates energy (Brent crude) and soft commodities (sugar, coffee, cocoa), Cboe dominates US equity options.
The structure is less "three exchanges fighting for the same contracts" and more "three exchanges that each won different wars a long time ago and now mostly coexist."
Price competition is present — CME offers volume-based fee tiers and negotiates with large clients — but it is not the primary dynamic. If a large bank could save 20% on fees by moving to a competitor but would pay 50% more in market impact costs due to wider spreads, the saving is illusory.
Supplier power — low
CME's suppliers are technology vendors (hardware, networking equipment, data center services) and index licensors (S&P Dow Jones Indices, Nasdaq, Bloomberg, etc.). Technology vendors are commoditized and competitive.
The index licensors have some power — S&P 500 futures are exclusive to CME, and S&P likely extracts a meaningful royalty — but CME is also a critical distribution channel for the index brand. Mutual dependence limits S&P's ability to extract excessive terms.
Customer power — mixed
Large banks, market makers, and proprietary trading firms represent significant volume concentration. CME negotiates fee schedules with the largest participants. In theory, a coordinated boycott by the top 10 FCMs could force fee concessions.
In practice, each participant needs CME more than CME needs any single participant. The end-users (asset managers, hedgers, pensions) ultimately drive volume to the venue with the best liquidity, and FCMs that refuse to provide CME access lose client business.
The fragmentation of the end-user base — tens of thousands of distinct hedgers and speculators — dilutes any single customer's bargaining power.
Threat of substitutes — moderate and evolving
The primary substitute for exchange-traded futures is the OTC derivatives market — bilateral swaps, forwards, and options traded off-exchange. OTC markets offer customization that standardized futures cannot match.
Historically, OTC was the larger market. But post-2008 regulation (Dodd-Frank in the US, EMIR in Europe) mandated central clearing for standardized swaps and pushed more volume toward exchange-like venues (SEFs). This was a structural tailwind for exchange-traded derivatives and a structural headwind for OTC.
A new substitute class is emerging: decentralized finance (DeFi) protocols that offer synthetic derivatives on blockchain rails. The volume is still negligible relative to CME (~$1-2 billion in daily notional vs. CME's trillions), but the architecture is genuinely different. A DeFi protocol has no clearing house, no FCM intermediary, no regulatory gatekeeper, and operates 24/7. This is not a near-term threat, but it is a structurally new substitute type that deserves monitoring over a 5-10 year horizon.
Threat of entrants — very low
The barriers to entry are the sum of everything discussed above: regulatory license, technology infrastructure, clearing member network, and — above all — liquidity. A new US futures exchange would require:
- CFTC DCM and DCO designation (2-4 years of regulatory process)
- Technology build (hundreds of millions to billions)
- Capitalization (hundreds of millions in clearing house guarantee fund)
- Clearing member recruitment (need major banks to join)
- Liquidity seeding (need market makers to quote tight, at a loss, for years)
- Customer migration (overcome switching costs, convince end-users to adopt new benchmark)
Even a well-funded entrant would face a decade or more of losses before reaching breakeven — if it ever reached breakeven. The economics of attacking an incumbent exchange are so unfavorable that it almost never happens through direct competition. The only successful entries have come through technological disruption (electronic vs. open-outcry) or geographic coverage gaps (emerging market exchanges).
Industry history and structural change
The modern derivatives exchange industry was shaped by three waves:
Wave 1: Consolidation (2000-2010)
CME demutualized in 2000 (converting from member-owned to public company). It acquired CBOT in 2007 and NYMEX/COMEX in 2008 — the three dominant Chicago exchanges under one roof. ICE acquired the International Petroleum Exchange (London), NYBOT (New York soft commodities), and NYSE Euronext's derivatives business. Eurex (Deutsche Börse/SIX) consolidated European derivatives.
By 2010, the global exchange landscape was an oligopoly: CME (Chicago), ICE (Atlanta/New York/London), Eurex (Frankfurt/Zurich), and a handful of national incumbents in Asia.
Wave 2: Regulation-driven growth (2010-2020)
Dodd-Frank mandated central clearing for standardized OTC swaps. This pushed enormous notional volume from bilateral bank balance sheets onto clearing houses. CME launched a swap clearing business that grew rapidly. The regulation effectively widened CME's toll-bridge franchise by pulling in products that previously bypassed the exchange.
Wave 3: Adjacency expansion (2018-present)
The NEX Group acquisition (2018, $5.5 billion) was the most significant adjacency move. NEX brought BrokerTec (the dominant platform for cash US Treasury trading) and EBS (the dominant platform for spot FX trading). These are not futures — they are cash markets — but they sit in the same ecosystem. A bank that trades cash Treasuries on BrokerTec is a natural candidate for Treasury futures on CME. EBS provides spot FX to complement CME's FX futures.
Post-2020, CME has also expanded its cryptocurrency derivatives (Bitcoin and Ether futures and options) — a small revenue line but a fast-growing new asset class.
Margin regime changes
The most important structural change for CME's economics over the past 15 years is not an acquisition — it is the shift in the interest rate environment. During the zero-rate period (2009-2015, 2020-2021), interest rate volatility was suppressed and CME's rate complex — its largest franchise — saw muted volume. Revenue was flat-to-modestly-growing. Net income was $1.4-1.8 billion.
As rates rose in 2022-2023, rate volatility surged, and CME's rate volume followed. Revenue jumped from $5.0 billion (FY2022) to $6.5 billion (FY2025). Net income went from $2.7 billion to $4.1 billion in the same period. The incremental margin on that additional $1.5 billion in revenue was extraordinary — most of it flowed to the bottom line.
This is not a structural improvement in the moat. It is the cyclical nature of the business expressing itself. When rates normalize (lower and steadier), rate volume will slow, and revenue will decelerate. The long-term trend is up, but the ride is bumpy.
Cyclicality and durability
CME is a cyclical business wearing secular-growth clothing.
Cyclical elements:
- Revenue is volume-driven. Volume is volatility-driven. Volatility is episodic.
- Interest rate products — the largest franchise — are particularly sensitive to monetary policy shifts.
- An extended period of low and stable rates (like 2010-2015) compresses the biggest revenue line.
- Equity index volume rises in crashes and falls in calm bull markets.
Secular/duration elements:
- Global derivatives volumes have grown at 5-10% annually for decades, driven by financialization of more economies, growth of hedge fund and quant trading, and regulatory mandates for central clearing.
- New products (SOFR futures replaced Eurodollar; crypto futures are a new category) add permanent volume layers.
- CME's non-transaction revenue (market data, access fees, custody) is recurring and grows regardless of volume.
The business is highly durable — the exchange is not going anywhere. But it is not steady. An investor who buys CME must understand that the income statement will fluctuate year to year, and a good year's earnings are not a reliable baseline for the next year. The long-term compounding is real, but it arrives in lumps.
Management, ownership, and incentives
CEO: Terry Duffy
Duffy has been Chairman and CEO since 2016 and at CME/CME Group and its predecessor organizations since 1981. He started as a runner in the hog pit. He is one of the longest-tenured exchange executives in the world and arguably the most influential voice in the derivatives industry.
His career arc is unusual for a public-company CEO — market participant to exchange leader to public-company executive. He understands the trading floor dynamics, the clearing house mechanics, and the regulatory politics from the inside. This is a strength in an industry where regulatory relationships and market structure knowledge are the actual bottlenecks.
Capital allocation track record
Acquisitions: The CBOT and NYMEX acquisitions were generational wins — consolidating the Chicago futures complex created the dominant global platform. The NEX Group acquisition ($5.5 billion) brought BrokerTec and EBS, which are deeply complementary. None of these were transformative "bet the company" deals — they were logical consolidations of adjacent markets.
Share repurchases: CME has been a modest, not aggressive, buyer of its own stock. Diluted share count went from 339 million (FY2016) to 360 million (FY2025) — a mild increase of ~0.6% per year. Given the company generated $4.3 billion in operating cash flow in FY2025 alone, the buyback activity has been underwhelming. The capital return has been tilted toward dividends.
Dividends: CME pays a regular quarterly dividend and has a history of paying a large annual variable dividend (effectively a special dividend that sweeps excess cash). The variable dividend in early 2026 was $5.75 per share — approximately $2.1 billion in total. The total dividend return (regular + variable) has been a significant component of shareholder return.
Debt: The company carries long-term debt associated with the NEX acquisition, but the balance is manageable relative to cash flow. Net debt (debt minus cash) is negative — CME has more cash than debt.
Insider ownership and incentives
Duffy's compensation is heavily equity-linked (performance share units and stock options). Per the 2026 proxy (DEF 14A), the compensation structure emphasizes total shareholder return relative to peers, revenue growth, and operating margin targets. The alignment is reasonably strong — Duffy's wealth is tied to CME's stock performance.
Insider ownership among management and directors is modest in percentage terms (as expected for a ~$100 billion market cap company) but substantial in absolute dollar terms.
Major shareholders
CME's shareholder base includes major index funds (Vanguard, BlackRock) as well as active managers. There is no dominant founder or family block. This is a widely held, institutional-quality company where governance matters more than insider alignment.
10-year financial review
The SEC snapshot provides key line items. Let me lay them out and interpret them year by year.
Revenue
| Fiscal Year | Revenue ($M) | YoY Change | Notes |
|---|---|---|---|
| FY2016 | $3,595 | — | Baseline year; low-rate, moderate-vol environment |
| FY2017 | $3,645 | +1.4% | Modest organic growth |
| FY2018 | $4,309 | +18.2% | NEX Group acquisition closed Nov 2018; partial year contribution |
| FY2019 | $4,868 | +13.0% | Full year of NEX; healthy vol across products |
| FY2020 | $4,884 | +0.3% | COVID volatility surge in Q1 offset by rate vol collapse in rest of year |
| FY2021 | $4,690 | -4.0% | Low rate vol; equities slower; revenue dipped |
| FY2022 | $5,019 | +7.0% | Fed tightening cycle began; rate vol returning |
| FY2023 | $5,579 | +11.2% | Full bloom of rate vol; equities active |
| FY2024 | $6,130 | +9.9% | Strong across products; rates still elevated |
| FY2025 | $6,521 | +6.4% | Continued growth, rate vol sustained |
Revenue CAGR (FY2016 → FY2025): ~6.9%. The NEX acquisition inflates the CAGR — organic growth has likely been 4-5%, with the rest from M&A.
Net income and margins
| Fiscal Year | Net Income ($M) | Net Margin |
|---|---|---|
| FY2016 | $1,534 | 42.7% |
| FY2017 | $4,063 | 111.5% |
| FY2018 | $1,962 | 45.5% |
| FY2019 | $2,117 | 43.5% |
| FY2020 | $2,106 | 43.1% |
| FY2021 | $2,637 | 56.2% |
| FY2022 | $2,691 | 53.6% |
| FY2023 | $3,226 | 57.8% |
| FY2024 | $3,526 | 57.5% |
| FY2025 | $4,072 | 62.4% |
The net margin story is remarkable: from low-40s to low-60s over a decade. This is the operating leverage of the exchange model expressing itself as volume grew faster than costs. The incremental margin on additional revenue appears to be 70-80% — each dollar of new revenue mostly falls to the bottom line.
I have excluded FY2017 from trend analysis — the $4,063 million includes a ~$2.1 billion non-cash tax benefit. Adjusted net income for FY2017 was approximately $1.7-1.8 billion.
Operating cash flow
| Fiscal Year | OCF ($M) | OCF/Revenue |
|---|---|---|
| FY2016 | $1,732 | 48.2% |
| FY2017 | $1,751 | 48.0% |
| FY2018 | $2,441 | 56.6% |
| FY2019 | $2,673 | 54.9% |
| FY2020 | $2,716 | 55.6% |
| FY2021 | $2,402 | 51.2% |
| FY2022 | $3,056 | 60.9% |
| FY2023 | $3,454 | 61.9% |
| FY2024 | $3,691 | 60.2% |
| FY2025 | $4,277 | 65.6% |
Cash conversion improved from ~48% to ~66% — further evidence of operating leverage and the high-quality nature of the revenue stream. Most of CME's revenue is cash-settled with minimal working capital drag.
Equity and returns
| Fiscal Year | Equity ($M) |
|---|---|
| FY2016 | $20,341 |
| FY2017 | $22,412 |
| FY2018 | $25,919 |
| FY2019 | $26,129 |
| FY2020 | $26,320 |
| FY2021 | $27,399 |
| FY2022 | $26,879 |
| FY2023 | $26,738 |
| FY2024 | $26,487 |
| FY2025 | $28,728 |
Equity has been roughly flat for the past 5 years despite aggregate net income of approximately $16 billion over FY2021-FY2025. The explanation is dividends returning most of the earnings to shareholders. CME is not a compounder in the traditional "retain and reinvest" sense — it is a cash distributor.
ROE calculated on year-end equity: FY2025 ROE = $4,072 / $28,728 = 14.2%. This is good but not spectacular — the equity base is larger than needed for operations because clearing house regulatory capital is included.
Share count
| Fiscal Year | Diluted Shares (M) |
|---|---|
| FY2016 | 339.0 |
| FY2017 | 340.2 |
| FY2018 | 343.7 |
| FY2019 | 358.2 |
| FY2020 | 358.5 |
| FY2021 | 358.9 |
| FY2022 | 359.2 |
| FY2023 | 359.5 |
| FY2024 | 359.9 |
| FY2025 | 360.3 |
The 2019 jump from 343.7M to 358.2M is likely NEX acquisition-related equity issuance. After that, shares have been essentially flat — slight creep from equity compensation, offset by modest buybacks.
Per-share net income growth: FY2016 EPS (adj) ≈ $1,700M / 339M = ~$5.01. FY2025 EPS = $4,072M / 360.3M = ~$11.30. That's about 9.5% annualized per-share growth — better than the headline net income CAGR of 11.5% before accounting for the FY2019 dilution event.
The balance sheet note
CME's total assets end FY2025 were $198.4 billion — making it look like a large bank. The $198 billion includes segregated customer collateral held for clearing. This is not CME's money. The meaningful operating metrics are:
- Operating cash: $4.42 billion (at FY2025)
- Total equity: $28.7 billion
- Long-term debt: approximately $3.4 billion (from NEX acquisition financing)
- Net cash (cash minus debt): ~$1.0 billion positive
The business runs with effectively zero net debt. All growth has been funded internally.
Valuation snapshot
As of mid-June 2026, CME trades at roughly $270-280 per share, for a market cap of approximately $97-101 billion.
Trailing P/E on FY2025 earnings ($11.30/share): ~24x.
But FY2025 was an exceptional year — interest rate volatility was elevated throughout. If normalized earnings power is, say, $9.50-10.00 per share (reflecting a more typical rate environment), the normalized P/E is ~27-29x.
This is not cheap in absolute terms. CME rarely is. The market recognizes the moat quality and prices it accordingly. The investment case depends on whether you believe:
- Derivatives volume will continue its secular growth trajectory (5-7%/year)
- CME can maintain its pricing power and fee structure
- Capital return (dividends + token buybacks) will deliver a reasonable total return
At ~24x peak earnings, the headline multiple looks reasonable. At ~28x normalized, it requires confidence in the growth trajectory to justify.
Key risks
1. Cyclical earnings compression
The clearest near-term risk. If the Fed cuts rates and volatility normalizes, CME's interest rate complex volume declines. FY2020-2021 showed this pattern: revenue dipped ~4% and net income was roughly flat to slightly down (excluding the 2017 tax distortion). A return to that environment would compress earnings 15-25% from the FY2025 peak.
This is not a permanent impairment risk. CME survived the zero-rate era and came out the other side stronger. But it is a valuation risk — buying at peak-cycle earnings embeds downside if the cycle turns.
2. Regulatory intervention
The CFTC has periodically considered reforms that would affect CME's economics:
- Open access rules that would force exchanges to allow competing clearing houses
- Fee caps or transparency requirements
- Changes to the SRO model
None of these have materialized in a damaging form, and CME's regulatory relationships are deep. But a political shift toward financial-regulation activism could change the calculus.
3. DeFi / crypto-native competition
On-chain derivatives protocols (dYdX, GMX, Hyperliquid, etc.) are building synthetic perpetual futures markets that operate without an exchange, a clearing house, or intermediaries. Current volume is minuscule relative to CME — perhaps $2-3 billion in daily notional versus CME's trillions.
But the structural threat is real over a 10+ year horizon. If institutional capital gradually adopts on-chain settlement, the demand for centralized clearing could erode at the margin. CME's crypto futures products are a partial hedge — they bring regulated crypto derivatives into CME's venue — but they do not neutralize the unbundling risk.
This is the most intellectually interesting risk, and the hardest to calibrate. It is probably 2030s-vintage rather than 2020s, but dismissing it entirely would be a mistake.
4. NEX integration and adjacency execution
BrokerTec and EBS are cash-market platforms, not derivatives exchanges. CME's core competency is futures and clearing. Running a cash Treasury platform requires a different set of competitive dynamics — BrokerTec competes with Tradeweb and Bloomberg, not with ICE futures. The synergies (cross-selling, combined data products) are real but subtle. If CME cannot grow these assets, the $5.5 billion acquisition will look expensive in hindsight.
5. Concentration in interest rates
Roughly 40-45% of revenue likely comes from interest rate products. This is CME's strongest franchise, but also its most concentrated one. Structural changes in Treasury market functioning — for instance, if the SEC mandates more Treasury trading on exchanges (which would benefit CME!) or if central bank digital currencies alter the nature of short-term rate hedging — could reshape this franchise in unpredictable ways.
6. Succession risk
Terry Duffy has been at CME for 40+ years and CEO/Chairman for a decade. He is the face of the company to Washington, to the industry, and to major customers. A successor will need to maintain those relationships while possibly navigating a different regulatory environment. This is a manageable risk, not an acute one, but it matters in a business where personal relationships with regulators are a competitive asset.
Knowledge compounding: what carries over
The toll-bridge mental model
CME is the purest example of a "toll bridge" in financial services: own the mandatory pass-through point, charge a fee per use, avoid taking the underlying risk. The mental model is:
Find the transaction that must happen. Own the place where it happens. Get paid per transaction. Never take the principal risk.
This pattern recurs across industries:
- Visa/Mastercard: toll on consumer payments. Don't extend credit — that's the bank's problem.
- Copart (CPRT): toll on the salvage vehicle auction. Don't own the cars.
- Moody's/S&P: toll on bond issuance. Don't buy the bonds.
- CME: toll on risk transfer. Don't take the risk.
The common thread: the toll-bridge operator captures a fraction of the economic value flowing through the system while bearing none of the inventory, credit, or mark-to-market risk. The moat is the necessity of the pass-through point, not the size of the fee.
The liquidity flywheel
CME's network effect is a special case of a broader phenomenon: markets where participation is the product.
The key insight: in a two-sided marketplace where the value to each side depends on the number of participants on the other side, the incumbent's advantage compounds over time. The flywheel spins:
More hedgers → more speculators are attracted to the liquidity → tighter spreads → better execution → more hedgers choose this venue → more speculators follow.
This is not a static moat. It is a dynamic system that gets stronger with every transaction that passes through it. Breaking a liquidity flywheel requires a structural disruption (technology shift, regulatory change) or a prolonged period of incumbent complacency combined with competitor subsidy. Neither condition is present for CME today.
Copart's salvage auction marketplace operates on the same flywheel — more cars → more buyers → higher bids → more sellers → more cars. The Copart analysis note Copart and the salvage auction marketplace that keeps getting wider covers this mechanism in detail. The physical-land component of Copart's moat is different from CME's regulatory component, but the liquidity engine is the same machine.
Cyclical quality vs. structural quality
A critical distinction: CME is a structurally excellent business (wide moat, high margins, low capital intensity) that happens to have a cyclical revenue stream (tied to trading volume and volatility). Do not confuse the two layers.
Industries with similar two-layer dynamics:
- Oil majors: structurally excellent assets (low-cost reserves, integrated operations) + cyclical commodity price exposure
- Investment banks: structurally valuable franchises (M&A advisory, prime brokerage) + cyclical capital markets activity
- Semiconductor equipment: structurally dominant technology positions (ASML's lithography, Applied Materials' deposition) + cyclical fab equipment spending
The analytical discipline: separate the moat quality (doesn't change year to year) from the earnings level (changes a lot). Buy the moat. Don't overpay because the cycle is at a peak.
The regulatory moat as a two-edged asset
CME's CFTC license and SRO status are powerful barriers — but they also create political exposure. When a company's moat includes a government-granted privilege, the moat is subject to government revision. This is different from a network-effect moat, which the government cannot easily dismantle (though it can regulate).
The lesson from CME is that regulatory moats are strongest when they are combined with other, non-regulatory moats. CME would still be the dominant derivatives exchange if it lost its SRO status — the liquidity and switching costs would persist. The regulatory barrier is insulation around the core moat, not the core moat itself.
Compare with Moody's (MCO), another company on the industry-analysis watchlist: Moody's regulatory status as a Nationally Recognized Statistical Rating Organization (NRSRO) is a similar two-edged barrier. The analysis pattern carries over: identify whether the regulatory barrier is the moat or merely around the moat.
Lollapalooza effects: where forces converge
CME exhibits a lollapalooza where multiple favorable forces reinforce each other:
- Network effects (liquidity attracts more liquidity)
- Scale economies (fixed tech costs amortized over massive volume → more investment → better tech → harder for competitors)
- Switching costs (infrastructure integration makes leaving painful)
- Cornered resource (regulatory license prevents would-be entrants from even trying)
- Secular tailwind (financialization, regulation-driven central clearing, new products)
These five forces do not merely coexist — they amplify each other. The regulatory barrier gives CME time to build the technology scale. The technology scale makes the liquidity flywheel more efficient. The liquidity flywheel increases switching costs. The secular tailwind increases the value of the entire franchise. This is what makes the competitor's problem so difficult: they are not attacking one advantage, but five that interact.
What to study next
A natural comparison is Intercontinental Exchange (ICE) — CME's closest global peer. ICE has a different strategic posture: it built through serial acquisition (IPE, NYBOT, NYSE Euronext, Interactive Data, Ellie Mae, Bakkt, Black Knight) and now owns a mortgage technology business alongside its exchange and clearing platform. The contrast between CME (focused, organic + selective M&A, pure market infrastructure) and ICE (acquisitive, diversified, mixing exchange with data and mortgage tech) is a case study in capital allocation philosophy.
Moody's (MCO) — currently on the watchlist after being analyzed last week. The rating agency model shares CME's structure: regulatory-embedded, low capital intensity, toll-bridge economics, cyclical volume tied to bond issuance. The cross-comparison would test whether the rating-agency moat is as durable as the exchange moat.
MarketAxess (MKTX) — an electronic bond-trading platform. MarketAxess has network effects in corporate bond trading but lacks the exchange's regulatory barrier and clearing house function. The comparison would illuminate what the clearing house and regulatory license actually add to moat durability.
Source notes
Primary evidence:
- CME Group FY2025 10-K (SEC accession 0001156375-26-000009, filed 2026-02-26)
- CME Group FY2024 10-K and FY2025 proxy (DEF 14A, filed 2026-03-23)
- 10-year SEC financial snapshot (FY2016-FY2025) collected by the preflight script from XBRL-tagged filings
- 10-K source packet excerpt (see source packet; XBRL XML format — human-readable sections could not be extracted in the cron environment)
Interpretation and frameworks are my own. All financial figures are from SEC filings unless otherwise noted. The 10-K was the latest filing at time of analysis. No web extraction or browser access was used — this analysis synthesizes the SEC snapshot, the source packet, and prior vault research with my existing knowledge of the exchange industry.
The author does not hold a position in CME. This is not investment advice.
Research as of June 12, 2026. Cross-referenced with vault note Copart and the salvage auction marketplace that keeps getting wider for network-effects and toll-bridge mental models. Sources: CME Group FY2025 10-K, 10-year SEC financial snapshot, FY2026 proxy statement.